CCL2 and neoplasm: LISA and RT-PCR assays demonstrated that gefitinib dose-dependently reduced CCL2 secretion in Cal-27 tumor spheroids (Figure 2I), while FMD significantly reversed gefitinib-induced CCL2 suppression at both protein (Figure 2I) and mRNA levels (Figure 2J).